HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Subscribe To Our Newsletter & Stay Updated
